Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease

Despite major advancements in the development of safer and more effective anticoagulant agents, bleeding complications remain a significant concern in the treatment of thromboembolic diseases. Improvements in our understanding of the coagulation pathways highlights the notion that the contact pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Badimon, Juan J., Escolar, Gines, Zafar, M. Urooj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781521/
https://www.ncbi.nlm.nih.gov/pubmed/36547434
http://dx.doi.org/10.3390/jcdd9120437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781521/
https://www.ncbi.nlm.nih.gov/pubmed/36547434
http://dx.doi.org/10.3390/jcdd9120437

Ejemplares similares